Navigation Links
Foundation Venture Capital Group Investment Shows Promise in Diagnosis of Alzheimer's Disease Using a Drop of Blood

NEW BRUNSWICK, N.J., Aug. 3, 2011 /PRNewswire-USNewswire/ -- A new diagnostic test for Alzheimer's disease (AD)  developed by biotech company Durin Technologies in New Jersey has shown promising results using antibody biomarkers in a drop of blood to identify presence of the disease, according to findings that appear online in PLoS ONE.

The research was made possible through an investment by Foundation Venture Capital Group (FVCG), LLC, a New Jersey Health Foundation affiliate that invests in start-up companies founded by researchers at the University of Medicine and Dentistry of New Jersey.  

"This research is an exciting step in AD diagnosis that seems extremely promising based on preliminary results," said James M. Golubieski, president of Foundation Venture Capital Group. "If, after further study, Dr. Nagele's research bears out, his success could help ease the suffering of millions of people worldwide as they struggle with this devastating illness."

Dr. Robert Nagele, founder of Durin Technologies and a researcher at the New Jersey Institute for Successful Aging at the UMDNJ-School of Osteopathic Medicine in Stratford, NJ, focuses his efforts on the concept that autoantibodies are involved in the degenerative mechanism of AD.

Study results published in PLoS ONE show the test, which uses microarray technology to analyze a small sample of blood, has a diagnostic sensitivity of 96 percent and a specificity of 92.5 percent and may be able to detect the disease even in its earliest stages, years before symptoms such as memory loss, poor judgment or erratic behavior appear.

"There's a dire need for an accurate, relatively non-invasive and inexpensive diagnostic test for AD," explained Dr. Nagele.  "A test that can detect the disease years before symptoms appear would make early intervention possible, a significant breakthrough as pharmaceutical companies are now working feverishly to develop new drugs that can stop or slow the progression of the disease."

As many as 5.3 million Americans, and 35 million people worldwide, are living with Alzheimer's disease, a devastating neurodegenerative illness characterized by memory loss, cognitive decline and widespread destruction of neurons in the brain.  

"Today, there is no definitive diagnosis for AD and no treatment to cure it," said George F. Heinrich, M.D., vice chair and chief executive officer of Foundation Venture Capital Group.  "We are thrilled to have played such an important role in helping to make this discovery possible.  It could represent a huge leap forward in the efforts to thwart this devastating disease."

For more information, contact James M. Golubieski, president of FVCG, at (908) 731-6601 or at

About Foundation Venture Capital Group
Foundation Venture Capital Group, an affiliate of New Jersey Health Foundation, was founded in 2006 to invest in commercially viable new start-up companies developing technology by faculty at UMDNJ. In addition to Durin Technologies, it has invested in:  

  • Actinobac Biomed Inc., developing a therapeutic agent targeting blood cells for the treatment of hematological malignancies;  the same agent seems to help in the treatment of other autoimmune diseases like psoriasis
  • Affineti Biologics, Inc., advancing research in the development of therapeutic and diagnostic products based on new discoveries in oral biology and dental medicine
  • CellXplore, Inc., engaged in the development of biomarker-based in vitro diagnostic assays for cancer; it has also developed technologies to diagnose mastitis
  • Celvive, Inc., working to develop technology to treat patients with chronic spinal cord injuries with their own adult stem cells
  • Longevica Pharmaceuticals, Inc., developing a chemoprotective agent that may keep normal cells healthy during cancer treatments (FVCG's equity interest in Longevica was sold to Rostock International, LTD, a subsidiary of a Moscow (Russia) based global investment firm)
  • Snowdon Pharmaceuticals, a drug discovery company focused on several major therapeutic areas.

SOURCE New Jersey Health Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kevin McHale Instrumental in Forming the Help Me Hear Foundation
2. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
5. The Oral Cancer Foundation Urges HPV Vaccination for Males
6. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
7. Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
8. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
9. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
10. Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1
11. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
Post Your Comments:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):